Pasithea Therapeutics (KTTA) Profit After Tax (2021 - 2026)

Pasithea Therapeutics has reported Profit After Tax for 6 years, with the latest figure at -$2.9 million in Q1 2026.

• Quarterly Profit After Tax rose 19.47% year-over-year to -$2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19.7 million (down 44.74% YoY) and the FY2025 annual result came in at -$20.4 million, down 46.78% from the prior year.
• Profit After Tax grew to -$2.9 million in Q1 2026 per KTTA's latest filing, from -$10.1 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$1.6 million in Q1 2022 and troughed at -$10.1 million in Q4 2025.
• A 5-year average of -$4.0 million and a median of -$3.6 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2024: Profit After Tax slumped 924.39% in 2022, then jumped 42.11% in 2024.
• Over 5 years, Profit After Tax stood at -$5.1 million in 2022, then fell by 7.47% to -$5.5 million in 2023, then surged by 42.11% to -$3.2 million in 2024, then sank by 218.17% to -$10.1 million in 2025, then surged by 71.62% to -$2.9 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$2.9 million, -$10.1 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.